Kilian Guse

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index2.6kcitations74works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(65), CAR-T cell therapy research(33), Cancer Research and Treatments(28), Viral Infectious Diseases and Gene Expression in Insects(27), Osteoarthritis Treatment and Mechanisms(5)

Publications74 total

Supplementary Figure S4. Oncolytic adenoviruses inhibit tumor growth, while trastuzumab transgene does not add to efficacy against HER2-negative breast cancer in vivo from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S1. Trastuzumab-coding oncolytic adenovirus mediates cytotoxicity in several HER2-positive and negative cancer cell lines from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S4. Oncolytic adenoviruses inhibit tumor growth, while trastuzumab transgene does not add to efficacy against HER2-negative breast cancer in vivo from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Data from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S5. Trastuzumab produced by oncolytic adenovirus in vivo binds to HER2-positive N87 cancer cells from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Interleukins, growth factors, and transcription factors are key targets for gene therapy in osteoarthritis: A scoping review
Frontiers in Medicine·2023· 15 citedOpen Access
Supplementary Figure S2. Oncolytic adenovirus coding for trastuzumab shows superior cell killing efficacy when dosed according to functional titers from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S5. Trastuzumab produced by oncolytic adenovirus in vivo binds to HER2-positive N87 cancer cells from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S1. Trastuzumab-coding oncolytic adenovirus mediates cytotoxicity in several HER2-positive and negative cancer cell lines from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S3. Antibody-dependent cell-mediated cytotoxicity by virus-produced trastuzumab is dependent on immune cells from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S6. NK-cells redistribute towards tumors and draining lymph nodes after treatment with trastuzumab-coding oncolytic virus from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S3. Antibody-dependent cell-mediated cytotoxicity by virus-produced trastuzumab is dependent on immune cells from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Data from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S6. NK-cells redistribute towards tumors and draining lymph nodes after treatment with trastuzumab-coding oncolytic virus from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Supplementary Figure S2. Oncolytic adenovirus coding for trastuzumab shows superior cell killing efficacy when dosed according to functional titers from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Data from Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1
2023Open Access
Data from Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Akseli Hemminki(39), Anna Kanerva(27), Vincenzo Cerullo(23), Sophie Escutenaire(14), Petri Nokisalmi(13), Maria Rajecki(13), Minna Oksanen(13), Iulia Diaconu(11), Leena Laasonen(11), Lotta Kangasniemi(10), Elina Haavisto(10), Merja Särkioja(10), Sari Pesonen(10), Mari Raki(9), Aila Karioja‐Kallio(8), Ari Ristimäki(8), Gerd Bauerschmitz(8), Sari Pesonen(7), Eerika Karli(6), Timo Joensuu(6)